Tinidazole

产品说明书

Print
Chemical Structure| 19387-91-8 同义名 : CP 12,574; CP12574; Tricolam; Teofarma; Simplotan; Fasygin; Fasigyne; Fasigyn; Fasigin; Farmasierra; Bioshik
CAS号 : 19387-91-8
货号 : A128250
分子式 : C8H13N3O4S
纯度 : 97%
分子量 : 247.27
MDL号 : MFCD00057217
存储条件:

Pure form Sealed in dry, room temperature

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(202.21 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 3 mg/mL(12.13 mM),配合低频超声助溶

动物实验配方:
生物活性
描述 Tinidazole is a 5-nitroimidazole active in vitro against a wide variety of anaerobic bacteria and protozoa. Tinidazole is an effective treatment against anaerobic microorganisms based on its pharmacokinetic characteristics (Cmax 51 microg/ml, t1/2 12.5h) and its excellent in vitro activity. Its long half-life allows once a day regimens. Tinidazole was recently approved by the Food and Drug Administration (FDA) for the treatment of infections caused by Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia[3]. Since tinidazole has no activity against aerobic bacteria, it must be combined with other antibacterial agents in the treatment of mixed infections involving aerobic and anaerobic bacteria[4]. TNZ (Tinidazole) outperforms ABZ (albendazole) in the treatment of Giardia infections in children from developing countries[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02934048 Therapeutic Duration ... 展开 >> Helicobacter Pylori Antimicrobial Susceptibility Test Eradication 收起 << Phase 4 Unknown June 2017 -
NCT03139253 Antimicrobial Susceptibility T... 展开 >>esting Triple Therapy 收起 << Phase 4 Not yet recruiting June 30, 2017 -
NCT03124420 Helicobacter Pylori Infection Phase 4 Completed - Taiwan ... 展开 >> Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Taipei, Taiwan, 10449 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.04mL

0.81mL

0.40mL

20.22mL

4.04mL

2.02mL

40.44mL

8.09mL

4.04mL

参考文献

[1]Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther. 2005 Dec;27(12):1859-84.

[2]Narcisi EM, Secor WE. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother. 1996 May;40(5):1121-5.

[3]Granizo JJ, Pía Rodicio M, Manso FJ, Giménez MJ. Tinidazol: un anaerobicida clásico con múltiples usos potenciales en la actualidad [Tinidazole: a classical anaerobical drug with multiple potential uses nowadays]. Rev Esp Quimioter. 2009;22(2):106–114

[4]Nord CE, Kager L. Tinidazole--microbiology, pharmacology and efficacy in anaerobic infections. Infection. 1983;11(1):54–60

[5]Escobedo AA, Ballesteros J, González-Fraile E, Almirall P. A meta-analysis of the efficacy of albendazole compared with tinidazole as treatments for Giardia infections in children. Acta Trop. 2016;153:120–127